Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst and Paul Goldberg

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

Shadman, Venur named deputy CMOs and endowed chairs at Fred Hutch

Fred Hutch has appointed Mazyar Shadman and Vyshak Alva Venur as deputy chief medical officers, effective April 1.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Novel antibody blocks Epstein-Barr virus, Fred Hutch study finds

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein-Barr virus, a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

March 13, 2026

Vol.52 No.10

Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

YOU MAY BE INTERESTED IN

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Shadman, Venur named deputy CMOs and endowed chairs at Fred Hutch

Novel antibody blocks Epstein-Barr virus, Fred Hutch study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows

YOU MAY BE INTERESTED IN

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Shadman, Venur named deputy CMOs and endowed chairs at Fred Hutch

Novel antibody blocks Epstein-Barr virus, Fred Hutch study finds

Never miss an issue!

Login

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”